FIELD: pharmaceuticals.
SUBSTANCE: group of inventions relates to the field of pharmaceuticals, namely to triterpene-based neuroprotective compositions, a pharmaceutical composition and a pharmaceutical dosage form for treatment of a neurological pathological condition, disease or disorder sensitive to triterpenes, as well as to methods for treatment of a neurological pathological condition, disease or disorder sensitive to triterpenes, to a time-delayed method for treatment of a stroke, to methods for preventing or reducing the occurrence rate of a neurological pathological condition, disease or disorder. The neuroprotective compositions comprise oleanolic acid or a pharmacologically acceptable salt thereof; ursolic acid or a pharmacologically acceptable salt thereof, and betulinic acid or a pharmacologically acceptable salt thereof in the ratio of 9 to 12:0.15 to 2.5:0.15 to 2.5. The pharmaceutical composition and the pharmaceutical dosage form comprise one or several pharmaceutical fillers and a triterpene-based composition. The methods for treatment of a neurological pathological condition, disease or disorder sensitive to triterpenes include introduction of a triterpene-based composition, or pharmaceutical composition, or pharmaceutical dosage forms in a dose of 0.1 to 100 mcg. The time-delayed method for treatment of a stroke includes, during the delayed period after the subject has suffered a stroke, introduction of a triterpene-based composition in a dose of 0.1 to 100 mcg; determination of the adequacy of the clinical response and/or therapeutic response of the subject to treatment with said composition; continued treatment with said composition or an increase or a reduction in said dose depending on the response. The methods for preventing or reducing the occurrence rate of a neurological pathological condition, disease or disorder in a population of subjects at risk of development thereof include introduction of a therapeutically effective amount of a triterpene-based composition to the subject.
EFFECT: group of inventions ensures production of an improved neuroprotective composition containing a synergistic mixture of oleanolic acid, ursolic acid, betulinic acid, taken in a certain ratio - 9 to 12:0.15 to 2.5:0.15 to 2.5, wherein the composition ensures increased expression of ARE genes, increased neuroprotection, and reduced cellular toxicity compared to other closely related compositions based on triterpenes on an equimolar basis, in a wide range of doses.
25 cl, 10 dwg, 14 tbl, 15 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF TREATING NEUROLOGICAL CONDITIONS WITH EXTRACT OF NERIUM SPECIES OR THEVETIA SPECIES | 2011 |
|
RU2606594C2 |
METHOD OF TREATING NEUROLOGICAL DISORDERS WITH CARDIAC GLYCOSIDES | 2011 |
|
RU2582223C2 |
METHOD OF TREATING NEUROLOGICAL CONDITIONS WITH CARDIAC GLYCOSIDS | 2011 |
|
RU2674679C2 |
USE OF PHARMACEUTICAL COMPOSITION CONTAINING CHOLINE ALFOSCERATE AND 2-ETHYL-6-METHYL-3-HYDROXYPYRIDINE SUCCINATE AS NEUROPROTECTIVE AGENT IN CEREBRAL ISCHEMIA | 2023 |
|
RU2819828C1 |
METHOD OF REDUCING DEMAGE TO NERVOUS CELLS | 2007 |
|
RU2464977C2 |
AGONISTS OF NEUROTROPHIN RECEPTORS AND THEIR USE AS MEDICAMENTS | 2011 |
|
RU2606622C2 |
USING MESENCHYMAL AND NEURONAL MARKER EXPRESSING STEM CELLS AND THEIR COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASES (VERSIONS) | 2017 |
|
RU2742828C2 |
PREPARATION FOR STIMULATING REGENERATION AND NEUROPROTECTION OF NERVE TISSUE AND METHOD OF USING SAME | 2023 |
|
RU2828544C1 |
CYSTEAMINE DIOXYGENASE-RESISTANT ANALOGUES OF CYSTEAMINE AND THEIR USE | 2016 |
|
RU2766579C2 |
COMPOUNDS AND PHARMACEUTIC COMBINATIONS FOR TREATMENT OF NEURODEGENERATIVE AND ISCHEMIC BRAIN DISEASES | 2012 |
|
RU2569302C2 |
Authors
Dates
2021-10-28—Published
2018-09-04—Filed